Pharmaceutical packaging is rated as "the second life" of pharmaceuticals as it is closely related to drug quality and safety, thus being an essential part of the pharmaceutical industry and an important industry concerning national economy and people's livelihood. However, pharmaceutical glass packaging produced by Chinese manufacturers are now mainly being used in global low-end pharmaceutical markets, while "Class I glass bottle" (made of glass with high chemical durability and high heat resistance) mainly depends on import, the proportion of which pharmaceutical glass packaging is only 8% in China, but 18% and 27% respectively in Europe and the United States. SGD Pharma is the world's leading manufacturer of pharmaceutical glass packaging and produces more than 2 billion glass containers every year, with2015 sales revenues of 290 million euros. SGD Pharma boasts of unique technologies with respect to pharmaceutical moldings and controlled products, and has five production bases in France, Germany, India and China, so that it is one of the few manufacturers capable of producing Class I pharmaceutical glass.
In May 2016, China Jianyin Investment Ltd. entered exclusive discussions with Oaktree Capital Corporation Limited for the acquisition of SGD Pharma.
In October 2016, China Jianyin Investment Ltd. finished buying controlling stakes in the SGD Project.
JIC will put into implementation the long-term strategy and business plan of SGD Pharma along with SGD Pharma's management for further R&D of high-quality product lines, support important investments in SGD Pharma's industrial facilities for the improvement of production capacity, and drive the development of emerging markets including the Chinese market for the continuous growth of its global business. Meanwhile, JIC will actively give full play to its advantages in laying out global brands, technologies, products and businesses with the purpose to encourage the upgraded development of China's pharmaceutical packaging industry.
"We sincerely welcome China Jianyin Investment Ltd. to be a new shareholder, whose long-term investment strategy fits well with our business model and strategic deployment.Moreover, our cooperation will provide us a new opportunity to achieve further growth in Asia. Given this, I look forward to China Jianyin Investment Ltd. with confidence." --Jürgen Sackhoff, President, SGD Pharma
Since the acquisition, JIC has selected and recruited experts and directors with rich experiences in the sector in which SGD is involved, and has optimized SGD's capital structure to reduce debt costs, contributing to a steady improvement of SGD's production capacity, attainment of mass production by I-type glass container plants, and 100% customer verification achievement. It also continues to expand new sales markets and acquire new customers throughout the world.